No Data
Eli Lilly Strikes $3.2 Billion Deal to Acquire Morphic
Eli Lilly (LLY) will buy biopharmaceutical company Morphic (MORF) for roughly $3.2 billion in a bid to expand its immunology portfolio with oral therapies targeting cell proteins for chronic diseases.
Eli Lilly (LLY) to Buy Morphic for $3.2B, Boost IBD Presence
A Quick Look at Today's Ratings for Morphic(MORF.US), With a Forecast Between $57 to $64
On Jul 09, major Wall Street analysts update their ratings for $Morphic(MORF.US)$, with price targets ranging from $57 to $64.Wells Fargo analyst Derek Archila maintains with a buy rating, and
Express News | RBC Capital Downgrades Morphic Holding to Sector Perform, Lowers Price Target to $57
Morphic Holding Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/09/2024 1.42% RBC Capital $70 → $57 Downgrades Outperform → Sector Perform 03/08/2024 17.44%
TD Cowen Downgrades Morphic Holding to Hold From Buy
Morphic Holding (MORF) has an average rating of outperform and price targets ranging from $30 to $64, according to analysts polled by Capital IQ.Price: 55.80, Change: +0.06, Percent Change: +0.11